Outliving Cancer: Recent Episodes
Dr. Robert Nagourney
“Outliving Cancer” brings a new perspective to the treatment of human malignancy.
Drawing upon years of experience, Dr. Robert Nagourney, Medical oncologist and Laboratory scientist brings his unique insights into the diagnosis, causes and treatments of this disease.
Join Dr. Nagourney as he explores the cellular origins of human cancer and examines better ways to use existing drugs, targeted agents and a growing number of novel combinations to successfully confront a disease that today is the 2nd leading cause of death in America. It is Dr. Nagourney’s intent to provide cancer patients with the tools that they will need to “outlive their cancers”.
Tom Stockwell, whose son passed away from a rare cancer shortly after being diagnosed at age 18, has focused on helping others find personalized treatment and ultimately, hopefully, a cure. On today’s episode, Dr. Nagourney talks with Tom.
Dr. Nagourney continues his discussion on the details of a disease that is so important to millions of Americans as he interviews Maria Lewis, who overcame advanced cancer several years ago by using functional profiling.
Dr. Nagourney discusses the details of a disease that is so important to millions of Americans as he interviews Maria Lewis, who overcame advanced cancer several years ago by using functional profiling.
Dr. Nagourney highlights several remarkable examples of results for patients of advanced years in this episode of Outliving Cancer.
The influence of age on cancer therapy. Dr. Nagourney examines the process of aging and its impact on cancer care.
Dr. Nagourney discusses how human tumor biology is evolutionary. If we consider how cancers adapt to micro-environmental stressors, many of which we call
therapies, we see the process of evolution accelerated as cancer cells divide. By condensing evolutionary adaptation, cancers can outdo our best therapies.
Dr. Nagourney examines the important distinction between gene tests and functional tests. It is critically important that all patients understand this fundamental distinction if they are to use functional profiling to gain the upper hand in their cancer management.
Dr. Nagourney discusses how drugs gain FDA approval and go on to clinical application but fail to realize their full potential as rigid guidelines undermine the intelligent use of active treatments and combinations.
Cancer patients today confront a dizzying array of treatment options but current “protocol-driven” therapies have had little impact on survival. Patients need actionable information and Dr. Nagourney provides just that.